Clinical Trial

Impact of Sleep Disturbance on Cognition and Quality of Life in Breast Cancer

Study acronym: ICANSLEEP
Recruiting
View on ClinicalTrials.gov →
Summary
Patients treated for breast cancer frequently complain of sleep disturbances, about 40% of them. Of the sleep disturbances experienced by patients, insomnia is the most common complaint. The prevalence of insomnia complaints is higher in breast cancer patients compared to other types of cancer, and is also higher than in the general population (between 20% and 70% in breast cancer patients vs 30% in the general population). A recent study indicates that sleep complaints concern 25% of patients even before diagnosis, and 46% (including 18% complaining of insomnia) at the time of diagnosis, showing the negative impact of the announcement of the pathology on the subjective quality of sleep, and particularly on symptoms suggestive of insomnia. However, objective information on a modification of sleep patterns in breast cancer remains scarce and does not allow us to conclude. In particular, previous studies have focused only on the effects of chemotherapy and have not always included a control group, limiting the significance of their results. The links with cognitive and psychopathological processes and the underlying mechanisms are not clearly demonstrated in this pathology. Finally, taking into account patients' complaints, it appears necessary to limit sleep disorders in breast cancer in order to improve patients' quality of life using non-medicinal and easy-to-implement approaches.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-06-08; most recent amendment 2025-09-17.
Status change: Not Yet Recruiting → Recruiting 2023-05-17
Trial Details
NCT Number NCT05414357
Lead Sponsor Centre Francois Baclesse
Collaborators: UMR_S 1077 Inserm-EPHE-Normandie Université
Conditions Breast Cancer, Sleep, Quality of Life
Enrollment 75 participants
Start Date 2023-03-20
Primary Completion 2027-03 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2025-09-22